Background: The emergence of carbapenem resistance among gram-negative bacilli (GNB), mediated by carbapenemase production, has necessitated the development of a simple and accurate device for detecting minimum inhibitory concentrations (MICs) and resistance mechanisms, especially carbapenemase production. We evaluated the performance of the BD Phoenix NMIC-500 panel (BD Diagnostic Systems, Sparks, MD, USA) for antimicrobial susceptibility testing (AST) and carbapenemase-producing organism (CPO) detection.
INTRODUCTION
The global spread of carbapenemase-producing Enterobacteriaceae, P. aeruginosa, and Acinetobacter species is a critical medical and public health issue causing both nosocomial and community-acquired infections [1, 2] . Carbapenems are key antimicrobials in the clinical field, as they are considered the final line of defense against multidrug-resistant (MDR) gram-negative bacilli (GNB) infections [3] [4] [5] . Resistance to carbapenems mediated by the acquisition of carbapenemase production is increas-ingly reported [6] . Carbapenemese production by bacterial hosts induces resistance to nearly all β-lactam drugs and is associated with MDR phenotypes [7] . Therefore, the dissemination of carbapenemase-producing organisms (CPO) is considered a public health emergency in Korea, especially following outbreaks of Klebsiella pneumoniae carbapenemase-2 (KPC-2)-producing Klebsiella pneumoniae in 2011 and carbapenemase-producing carbapenem-resistant Acinetobacter baumannii in 2004 [8, 9] . The potential for further escalation of this scenario should not be ignored, as these genes are associated with mobile genetic elements, and the emergence of novel enzyme types and variants is expected [7] . Thus, rapid and accurate detection of antimicrobial resistance and resistance mechanisms is important to prevent the dissemination of MDR bacteria [10] .
Carbapenemases are usually classified into three classes of β-lactamases (according to their amino acid identity): Ambler class A (serine-β-lactamases), B (metallo-β-lactamases; MBLs), and D (oxacillinases; OXAs) β-lactamases. In addition, Ambler Class C β-lactamase (AmpC β-lactamase) could induce resistance to carbapenems in bacterial hosts, when accompanied with additional resistance mechanisms such as porin loss [11] [12] [13] . Ceftazidime-avibactam was recently introduced as a new compound combining ceftazidime and a novel β-lactamase inhibitor with activity against various β-lactamases produced by MDR GNB [14] . Avibactam was first reported in 2003; it is a β-lactamase inhibitor against Ambler class A and C β-lactamases, and this agent also possesses activity against some of Ambler class D enzymes [15, 16] . The addition of avibactam to ceftazidime improves its in vitro activity against Enterobacteriaceae and Pseudomonas aeruginosa [17] . Recent study has revealed that ceftazidime-avibactam exhibits a good outcome to treat patients infected with KPC-producing strains [18] .
The BD Phoenix NMIC-500 panel (BD Diagnostic Systems, Sparks, MD, USA) has been designed with advantageous properties for determining carbapenem minimum inhibitory concentrations (MICs), as well as CPO detection, compared with a previous panel [GN-27 NMIC203 (BD Diagnostic Systems)] [19] . By including CPO detection and ceftazidime-avibactam MIC determination in routine antimicrobial susceptibility testing (AST), the BD Phoenix NMIC-500 panel could offer valuable support for clinical studies examining different therapeutic strategies for infections caused by CPOs. To our knowledge, the performance of this panel has not been evaluated so far. We evaluated the performance of the BD Phoenix NMIC-500 panel for AST and CPO detection with clinical GNB isolates. 
METHODS

Bacterial strains
BD Phoenix analysis
AST was conducted according to the manufacturer's instructions. Briefly, the identification (ID) broth was inoculated with bacterial colonies from pure cultures adjusted to 0.5-0.6 McFarland (McF) standard using a Phoenix spectrophotometric device. The standardized ID broth suspension (25 µL) were transferred to the Phoenix AST broth, which was supplemented with one drop of the Phoenix AST indicator for detecting organism growth before being added to the panels. The panels were sealed, logged, and loaded into the Phoenix device. The results were interpreted using Epicenter data management software version 7.22A (BD Diagnostic Systems) after 16 hours of incubation.
Reference methods
The meropenem (range: 0. [20] . E. coli ATCC 25922 and P. aeruginosa ATCC 27853 were used as control strains, as recommended by the CLSI.
PCR and sequencing were performed for the carbapenem-resistant GNB isolates to identify the carbapenemase genes including KPC, New Delhi metallo-β-lactamase (NDM), imipenemase (IMP), Verona integron-borne metallo-β-lactamase (VIM), OXA-48-like, and OXA-23. PCR was performed using the following www.annlabmed.org https://doi.org/10.3343/alm.2019.39.5.470 amplification conditions: 94°C for five minutes, followed by 30 cycles of 94°C for 30 seconds, 58°C (KPC) or 60°C (OXA-48-like, IMP, VIM, and NDM) for 30 seconds, and 72°C for 30 seconds, followed by a final extension at 72°C for five minutes. To confirm the amplified products, they were directly sequenced using an automatic sequencer (model 3730xl; Applied Biosystems, Weiterstadt, Germany). The oligonucleotide sequences of the primer used are summarized in Table 1 .
Data analysis
The accuracy of the BD Phoenix NMIC-500 panel was calculated using categorical agreement (CA), essential agreement (EA), minor error (mE), major error (ME), and very major error (VME), which were determined by comparing its MIC results to the BMD results according to the CLSI breakpoints [21] . The Phoenix system results were considered CA if they agreed with the susceptible, intermediate, and resistant categories of the BMD results. Results were deemed EA when the MIC results using the BD Phoenix NMIC-500 panel and BMD were identical or 2-fold different. Results were deemed mE when one set of the AST results was intermediate while the other set was resistant or susceptible. Results were deemed ME when the Phoenix system MIC results were resistant, while the BMD results were susceptible. Results were deemed VME when the Phoenix system indicated susceptibility and the BMD indicated resistance.
The accuracy of CPO detection was determined as follows: carbapenemase production was considered positive when the Phoenix system results showed "carbapenemase producer," "class A carbapenemase producer," "class B carbapenemase producer," or "class D carbapenemase producer"; otherwise, it was considered negative. In terms of CPO classification, "carbapenemase producer" were considered as "not classified." In addition, "class A carbapenemase producer," "class B carbapenemase producer," and "class D carbapenemase producer" were considered as correctly classified when corresponding to the same class determined by conventional PCR, but were considered as incorrectly classified when corresponding to a different class. Abbreviations: AST, antimicrobial susceptibility testing; BMD, broth microdilution; EA, essential agreement; CA, categorical agreement; S, susceptible; I, intermediate; R, resistant; mE, minor error; ME, major error; VME, very major error.
RESULTS
Enterobacteriaceae Table 2 and Fig. 1 detail the AST results obtained using the BD Phoenix NMIC-500 panel and BMD with 409 clinical Enterobacteriaceae isolates. Most antimicrobials showed high CA and EA rates ( > 90%), except for imipenem, which showed a CA rate of 87.2%. In addition, only seven VME were observed, and the ME rates were 3%. Table 3 and Fig. 2 detail the CAs, EAs, as well as mE, ME, and Abbreviations: AST, antimicrobial susceptibility testing; BMD, broth microdilution; EA, essential agreement; CA, categorical agreement; S, susceptible; I, intermediate; R, resistant; mE, minor error; ME, major error; VME, very major error. VME numbers and rates for 41 clinical P. aeruginosa and A. baumannii isolates. High agreement was observed between the results of BD Phoenix NMIC-500 panel and BMD. The CA and EA rates were all > 90%, ranging from 92.7% to 100% and from 97.6% to 100%, respectively, except for the EA of imipenem, which was 87.8%. Only one ME was identified for imipenem. 
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DISCUSSION
The carbapenem MICs obtained using the BD Phoenix NMIC-500 panel were higher than those obtained by BMD. The ME rates were slightly elevated, while VME was identified in only 1.5% (7/ [23] evaluated the BD Phoenix CPO Detect system (BD Diagnostic Systems), which is an AST panel similar to the BD Phoenix NMIC-500 panel, and showed that 97.3% (107/110) of class A carbapenemases, 95.6% (87/91) of class B carbapenemases, and 100% (35/35) of class D carbapenemases were positively identified. However, although the dual carbapenemase producers were positively identified, the system could not classify them. In the same study, Carba NP (bioMérieux, St. Louis, MO, USA) could positively identify 98.2% of class A, 98.9% of class B, and 94.3% of class D producers, as well as the dual carbapenemase producers. Although Carba NP showed high CPO detection performance, this kit required extra time for AST. In addition, Carba NP requires a chromogenic medium, which exhibits different shades of color that could be challenging for laboratory staff to interpret. In contrast, the BD Phoenix NMIC-500 panel was easier to interpret as it does not require a chromogenic medium, and CPO detection was more rapid.
The BD Phoenix NMIC-500 panel could identify carbapenemase production in 86.7% (13/15) of the dual carbapenemaseproducing isolates; however, it could identify only one class of carbapenemase out of two in dual carbapenemase producers. Moreover, the remaining two isolates, which were correctly identified by the BD Phoenix NMIC-500 panel, harbored two carbapenemase genes within the same class. Thomson et al. [23] also suggested that most dual carbapenemase producers were not correctly identified using the BD Phoenix CPO Detect and that this should be improved in subsequent panels.
Ceftazidime-avibactam is the most active compound tested against KPC-producing isolates. Ceftazidime-avibactam was introduced to treat infections caused by KPC-producers, and its ability has been demonstrated [24, 25] . Our results showed that ceftazidime-avibactam could suppress the action of 94.4% (67/ 71) of KPC-producing isolates. Thus, ceftazidime-avibactam has potential to combat carbapenem-resistant Enterobacteriaceae.
A limitation of this study was that carbapenemase-non-producing carbapenem-resistant organisms were not included to evaluate the accuracy of CPO detection. This should be further investigated to confirm the accuracy of this panel.
In conclusion, the BD Phoenix NMIC-500 panel showed promising ability for MIC determination and CPO detection in a large number of clinical GNB isolates. The BD Phoenix NMIC-500 panel showed high agreement with conventional methods. By including carbapenemase detection and ceftazidime/avibactam MIC determination in routine AST, the BD Phoenix NMIC-500 panel offers valuable support for clinical studies examining different therapeutic strategies for infections caused by such organisms. This capability, in conjunction with good infection control, can help ensure that medical institutions are at minimal risk of a CPO pandemic.
